Nvidia Partner Hon Hai Meets Sales Estimates on Strong AI Demand
Revenue totaled NT$1.8 trillion ($62 billion) in the three months to June, largely in line with analysts' expectations, results showed Saturday. Hon Hai expects third-quarter sales to grow sequentially and year-on-year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Amid AI boom, veteran analyst reboots AMD, Supermicro stock price targets
Amid AI boom, veteran analyst reboots AMD, Supermicro stock price targets originally appeared on TheStreet. Nvidia () stock typically hogs all the AI spotlight, but if you look at the bigger picture, two other names deserve a deeper look. AMD () and Super Micro Computer () stock have been silently positioning themselves at the heart of AI's next big upgrade cycle. 💵💰💰💵 The former is pushing for new GPUs to hyperscalers, desperate for an alternative, while the latter is building the racks that make all that horsepower usable at scale. With that said, a bold and fresh analyst take this week shows why these tech giants are poised to chip away at Nvidia's massive lead. One thing is clear from recent weeks: Nvidia's AI crown isn't as untouchable as it looks on paper. AMD, in particular, has been showing that it isn't content playing second fiddle. CEO Lisa Su recently dropped a bombshell at the company's big 'Advancing AI' event, unveiling the new Instinct MI350 series. These powerful new GPUs are built to supercharge AI, delivering up to four times more compute performance and a 35× boost in inference. More importantly, the top AI juggernauts in Meta, Microsoft, and OpenAI are already kicking the tires on these chips. That shows the bellwethers in the hyperscaler space are itching for a serious Nvidia AMD fires up the accelerator race, Supermicro is locking down the racks to run them. Though it was primarily a key player in motherboards and chassis, Supermicro now considers itself a leading hyperscale AI systems powerhouse. Last month, Saudi-based DataVolt signed a jaw-dropping $20 billion multi-year deal to deploy Supermicro's liquid-cooled GPU racks across AI campuses in Saudi Arabia and the U.S. Such an enormous order indicates that Supermicro's modular, dense, and energy-efficient designs are critical in powering AI mega-centers. Nvidia still calls the shots in the AI space, but AMD's MI350X ramp and Supermicro's hyperscale push highlight room for major competition. More Tech Stock News: Analyst reboots IonQ stock price target for surprising reason Apple could make big change to Siri, delight fans Veteran analyst issues big Broadcom call, shakes up AI stock race And with the MI400 series and Helios AI Rack on deck for next year, it's clear AMD and Supermicro are gunning to rewrite the script on AI. Mizuho's latest bullish note shows how AMD and Supermicro offer strong upside for chipmakers looking to feed AI's insatiable compute appetite. Mizuho analyst Vijay Rakesh stuck with his Outperform call on AMD stock but raised his 12-month price target to $152 from $135. That implies a 10.2% bump from Thursday's close at $137.91 and a 12.6% increase from the previous price target. Rakesh called out a 'slightly better MI355X ramp' in the second half of this year. That's huge, considering the new Instinct series is arguably AMD's most promising play at challenging Nvidia's AI accelerator dominance. Hyperscalers want alternatives, and AMD's open-standard hardware is firmly on their Mizuho didn't sugarcoat everything. It left its near-term numbers mostly unchanged, keeping the June-quarterly sales forecast at $7.40 billion and EPS at 47 cents, both just shy of consensus. For the full year, Rakesh has trimmed its EPS slightly to $3.90. Nevertheless, the real story is what happens next, with AMD's robust margin mix and high-end AI chips offsetting any short-term softness. Over at Supermicro, Rakesh sees plenty to like, too. He nudged his price target to $47 from $40, a healthy 17.5% bump, while keeping a Neutral rating. The veteran analyst believes the demand for AI servers is running hot. Sizeable shipments for Tier-2 Microsoft Azure partners, plus a steady drumbeat of orders for Supermicro's liquid-cooled GPU, point to an excellent runway ahead. Also, Rakesh models the Saudi Arabia DataVolt deal, adding $2.5 billion in annual sales starting next year, highlighting a massive ramp-up in top-line AI boom, veteran analyst reboots AMD, Supermicro stock price targets first appeared on TheStreet on Jul 6, 2025 This story was originally reported by TheStreet on Jul 6, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
Undervalued and Profitable: This Artificial Intelligence (AI) Stock Has Soared 73% in 2025, and It Could Still Jump Higher
The booming demand for data center storage has supercharged Seagate Technology's growth in recent quarters, leading to tremendous upside for the stock. Seagate is trading at a discount to the broader market right now, and that could pave the way for attractive returns over the next several years. 10 stocks we like better than Seagate Technology Plc › Storage solutions provider Seagate Technology (NASDAQ: STX) has registered an outstanding rally on the stock market in 2025, rising an incredible 73% year to date and beating the Nasdaq Composite index's 7% return by a massive margin. This impressive performance can be attributed to robust growth in the demand for storage in data centers running artificial intelligence (AI) workloads. Let's dig into how AI is fueling Seagate's growth and see how it could pave the way for more upside in this technology stock. Seagate Technology's revenue in the first nine months of its fiscal 2025 increased almost 43% year over year to $6.65 billion. Even better, the company's non-GAAP (adjusted) income from operations has jumped more than fourfold during this period, thanks to higher margins. Management attributes this fantastic growth to the healthy demand for mass capacity storage in the cloud, which has created a tight supply environment and led to an increase in prices. Management remarked on the company's April earnings call that the growing storage demand "aligns with the cloud capex investment cycle and ongoing build-out of data center infrastructure to support AI transformations." Specifically, 90% of the storage in large-scale data centers is done with hard drives because of their cost efficiency and scalability. With the storage requirement in data centers expected to more than double between 2024 and 2028, Seagate estimates this could push annual revenue for the data center storage market to $23 billion by 2028, up from $13 billion last year. Seagate is in a solid position to make the most of this growth opportunity considering its 40% share of the global storage market. Not surprisingly, Seagate's outlook for the recently concluded fiscal fourth quarter was an impressive one. The company guided for $2.4 billion in revenue at the midpoint of its range, along with $2.40 per share in earnings. The top-line guidance is good for a 27% year-over-year increase, while earnings are on track to more than double from the prior-year period's reading of $1.05 per share. For the full fiscal year, Seagate could grow revenue 38%, while its adjusted earnings will jump more than sixfold to $7.91 per share. Importantly, the company should be able to sustain this momentum, thanks to the tailwinds discussed above, and that sets the stage for strong returns. The potential earnings growth combined with Seagate's incredibly attractive valuation makes the stock a no-brainer buy. It is now trading at just 21 times trailing earnings and 16 times forward earnings estimates. The Nasdaq 100 index, meanwhile, has an average forward earnings multiple of 29, which means the stock trades at a significant discount to the tech sector overall. Investors looking for a fast-growing AI stock that's also reasonably priced would do well to buy Seagate before it flies higher. Before you buy stock in Seagate Technology Plc, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Seagate Technology Plc wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Undervalued and Profitable: This Artificial Intelligence (AI) Stock Has Soared 73% in 2025, and It Could Still Jump Higher was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on
